Universal Cells Inc. is a private biotechnology company based in Seattle, Washington that is enabling the field of regenerative medicine by creating stem cells that are universally compatible. Our technology is based on intellectual property exclusively in-licensed from the University of Washington and includes methods for genome editing in human stem cells via homologous recombination with recombinant adeno-associated virus (rAAV) vectors, as well as specific HLA-engineering strategies.
